DEINOVE : Emmanuel PETIOT becomes CEO of DEINOVE

Press release

EMMANUEL PETIOT BECOMES CEO OF DEINOVE Emmanuel PETIOT was formerly Director of Sales of NOVOZYMES in the United States. Jacques BITON, CEO of DEINOVE since 2007, is appointed Chairman of the Scientific Advisory Board. Paris January 9, 2013 - DEINOVE (Alternext Paris: Aldei) announces the appointment of Emmanuel PETIOT, formerly Director of Sales of NOVOZYMES North America, Inc. (the world leader in enzymes and microorganisms), as CEO of DEINOVE. Jacques BITON, CEO since 2007, is appointed Chairman of the Scientific Advisory Board of the company.

The primary goal of Emmanuel PETIOT will be to position the company internationally and to confirm its technological leadership by negotiating new agreements with corporate partners in the various markets targeted by DEINOVE. The company has now developed a powerful synthetic biology platform to optimize the natural enzymatic and metabolic properties of the Deinococcus bacteria. This highly innovative approach has attracted Emmanuel PETIOT, a senior executive in the field of enzymes and microorganisms. His extensive experience in biomass, biofuels and high value chemicals is a great asset for DEINOVE.
Emmanuel PETIOT was previously Director of Sales of NOVOZYMES North America Inc., the world leader in enzymes and microorganisms. For 9 years, he had a brilliant career in this Danish industrial biotechnology company, holding executive positions in marketing, sales and business development, both in Europe and the United States. He was also General Manager of the French subsidiary of NOVOZYMES. Previously, he held senior marketing and sales positions at Dow Chemical and Air Liquide. Emmanuel PETIOT graduated from EDHEC and the École Centrale, Paris.
"I am proud to become CEO of a company that many experts consider the rising star of the green technology sector. Building upon the great R&D achievements of DEINOVE, I will create value for the company and its shareholders by leading the DEINOL project to market, developing projects in green chemistry and speeding up our international partnerships" says Emmanuel PETIOT. "Jacques will continue to support DEINOVE by chairing our Scientific Advisory Board."
CEO since 2007, Jacques BITON has been the architect of the technological development of the company, making Deinococcus bacteria a unique technology platform that has already demonstrated its great potential for biomass degradation and bioethanol production. Jacques BITON is now the Chairman of the International Scientific Advisory Board of DEINOVE that includes Professor Miroslav RADMAN, one of the two founders of DEINOVE.
Jacques BITON comments: "Recruiting Emmanuel PETIOT is a great step for DEINOVE. His leadership will enable us to speed up the development of our technological and industrial partnerships. I will continue, within the Scientific Advisory Board, to explore the broad potential of Deinococcus bacteria and support the R&D teams. I am very proud of our achievements and look forward to working with Emmanuel."
Chairman of the Board and founder of DEINOVE with Miroslav RADMAN, Dr. Philippe POULETTY concludes: "Thanks to the work accomplished since 2006, the company is now positioned as a leader in bacterial technologies. With our Board of Directors, we chose Emmanuel PETIOT to build the next steps of value creation. With our technology platform and our leading intellectual property in the field of Deinococcus, Emmanuel and his team will establish strong corporate partnerships, explore new markets, and grow the company further."

1|2 DEINOVE | Press Release, January 9, 2013

Press release

About DEINOVE

DEINOVE (Alternext Paris: Aldei) is a biotechnology company that designs and develops new production systems based on bacteria with untapped potential: the Deinococcus. Taking advantage of the unique genetic properties and unusual robustness of Deinococcus, the synthetic biology experts at DEINOVE optimize the enzymatic and metabolic capabilities of these natural "micro-factories" to manufacture rare compounds or products that are not achievable using classic chemical and enzymatic processes: second generation bioethanol (DEINOL); enzymes for bioremediation of plastics (THANAPLAST™); new antibiotics (DEINOBIOTICS); terpenoids for chemistry, cosmetics and biopharmaceuticals (DEINOCHEM).
DEINOVE is currently focusing on making the DEINOL program for cellulosic bioethanol production a success. This program is granted with €8.9m by OSEO and is backed up by the sugar group TEREOS, the French leader and the second European producer of bioethanol. DEINOL recently achieved a worldwide breakthrough when a Deinococcus, selected and optimized by DEINOVE, has successfully turned wheat-based biomass into ethanol, in a single operation and without additives. In 2014, at the end of the laboratory pilot phase, TEREOS will be responsible for validating the full-scale process at its factory in Lillebonne (France), within the framework of a first non-exclusive license.
Listed on Alternext since April 2010, DEINOVE was founded by Dr Philippe POULETTY, General Partner of Truffle Capital, and Pr Miroslav RADMAN, Professor at the Faculty of Medicine of the Université René Descartes. With a workforce of about 30 people, it conducts R&D programmes in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and the VTT (Finland). The Company is headquartered in Paris, with laboratories located in the Cap Alpha Technology Park in Montpellier (France).
More information at www.deinove.com

Contacts

DEINOVE Emmanuel PETIOT CEO

Tel: + 33 4 67 59 36 04 [e-mail]
Elisabetta CASTELLI Director of Communications Tel: [phone]
[e-mail]

ATCG Press Marielle BRICMAN Press relations

Mob.: [phone] [e-mail]

2|2 DEINOVE | Press Release, January 9, 2013